261 related articles for article (PubMed ID: 24958817)
1. New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1.
Coleman N; Brown BM; Oliván-Viguera A; Singh V; Olmstead MM; Valero MS; Köhler R; Wulff H
Mol Pharmacol; 2014 Sep; 86(3):342-57. PubMed ID: 24958817
[TBL] [Abstract][Full Text] [Related]
2. Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-
Brown BM; Shim H; Zhang M; Yarov-Yarovoy V; Wulff H
Mol Pharmacol; 2017 Oct; 92(4):469-480. PubMed ID: 28760780
[TBL] [Abstract][Full Text] [Related]
3. Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Sankaranarayanan A; Raman G; Busch C; Schultz T; Zimin PI; Hoyer J; Köhler R; Wulff H
Mol Pharmacol; 2009 Feb; 75(2):281-95. PubMed ID: 18955585
[TBL] [Abstract][Full Text] [Related]
4. Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3.
Oliván-Viguera A; Valero MS; Murillo MD; Wulff H; García-Otín AL; Arbonés-Mainar JM; Köhler R
PLoS One; 2013; 8(3):e58614. PubMed ID: 23516517
[TBL] [Abstract][Full Text] [Related]
5. A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.
Oliván-Viguera A; Valero MS; Coleman N; Brown BM; Laría C; Murillo MD; Gálvez JA; Díaz-de-Villegas MD; Wulff H; Badorrey R; Köhler R
Mol Pharmacol; 2015 Feb; 87(2):338-48. PubMed ID: 25468883
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs.
Damkjaer M; Nielsen G; Bodendiek S; Staehr M; Gramsbergen JB; de Wit C; Jensen BL; Simonsen U; Bie P; Wulff H; Köhler R
Br J Pharmacol; 2012 Jan; 165(1):223-34. PubMed ID: 21699504
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Cardiovascular Function in Primary Hypertension in Rat by SKA-31, an Activator of
Kloza M; Baranowska-Kuczko M; Toczek M; Kusaczuk M; Sadowska O; Kasacka I; Kozłowska H
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450834
[TBL] [Abstract][Full Text] [Related]
8. Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca2+ -activated K+ -channels.
Hasenau AL; Nielsen G; Morisseau C; Hammock BD; Wulff H; Köhler R
Acta Physiol (Oxf); 2011 Sep; 203(1):117-26. PubMed ID: 21362152
[TBL] [Abstract][Full Text] [Related]
9. Activation of KCa3.1 by SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and hypertensive connexin40-deficient mice.
Radtke J; Schmidt K; Wulff H; Köhler R; de Wit C
Br J Pharmacol; 2013 Sep; 170(2):293-303. PubMed ID: 23734697
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1).
Christophersen P; Wulff H
Channels (Austin); 2015; 9(6):336-43. PubMed ID: 26217968
[TBL] [Abstract][Full Text] [Related]
11. SKA-31, an activator of endothelial Ca
Khaddaj-Mallat R; Mathew John C; Braun AP
Eur J Pharmacol; 2018 Jul; 831():60-67. PubMed ID: 29753043
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary hypertension in wild type mice and animals with genetic deficit in KCa2.3 and KCa3.1 channels.
Wandall-Frostholm C; Skaarup LM; Sadda V; Nielsen G; Hedegaard ER; Mogensen S; Köhler R; Simonsen U
PLoS One; 2014; 9(5):e97687. PubMed ID: 24858807
[TBL] [Abstract][Full Text] [Related]
13. Vascular Reactivity Profile of Novel KCa 3.1-Selective Positive-Gating Modulators in the Coronary Vascular Bed.
Oliván-Viguera A; Valero MS; Pinilla E; Amor S; García-Villalón ÁL; Coleman N; Laría C; Calvín-Tienza V; García-Otín ÁL; Fernández-Fernández JM; Murillo MD; Gálvez JA; Díaz-de-Villegas MD; Badorrey R; Simonsen U; Rivera L; Wulff H; Köhler R
Basic Clin Pharmacol Toxicol; 2016 Aug; 119(2):184-92. PubMed ID: 26821335
[TBL] [Abstract][Full Text] [Related]
14. Channelopathy-causing mutations in the S
Orfali R; Nam YW; Nguyen HM; Rahman MA; Yang G; Cui M; Wulff H; Zhang M
Cell Calcium; 2022 Mar; 102():102538. PubMed ID: 35030515
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels.
Brown BM; Shim H; Christophersen P; Wulff H
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():219-240. PubMed ID: 31337271
[TBL] [Abstract][Full Text] [Related]
16. A pharmacologic activator of endothelial KCa channels increases systemic conductance and reduces arterial pressure in an anesthetized pig model.
Mishra RC; Mitchell JR; Gibbons-Kroeker C; Wulff H; Belenkie I; Tyberg JV; Braun AP
Vascul Pharmacol; 2016 Apr; 79():24-31. PubMed ID: 26239885
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Targeting of KCa Channels to Improve Endothelial Function in the Spontaneously Hypertensive Rat.
Khaddaj Mallat R; Mathew John C; Mishra RC; Kendrick DJ; Braun AP
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31315169
[TBL] [Abstract][Full Text] [Related]
18. Channelopathy of small- and intermediate-conductance Ca
Nam YW; Downey M; Rahman MA; Cui M; Zhang M
Acta Pharmacol Sin; 2023 Feb; 44(2):259-267. PubMed ID: 35715699
[TBL] [Abstract][Full Text] [Related]
19. The Trials and Tribulations of Structure Assisted Design of K
Shim H; Brown BM; Singh L; Singh V; Fettinger JC; Yarov-Yarovoy V; Wulff H
Front Pharmacol; 2019; 10():972. PubMed ID: 31616290
[TBL] [Abstract][Full Text] [Related]
20. Laminar shear stress upregulates endothelial Ca²⁺-activated K⁺ channels KCa2.3 and KCa3.1 via a Ca²⁺/calmodulin-dependent protein kinase kinase/Akt/p300 cascade.
Takai J; Santu A; Zheng H; Koh SD; Ohta M; Filimban LM; Lemaître V; Teraoka R; Jo H; Miura H
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H484-93. PubMed ID: 23792675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]